In a recent study posted to the medRxiv* preprint server, researchers evaluated the messenger ribonucleic acid (mRNA)-1273 vaccine effectiveness (VE) against severe acute respiratory syndrome ...

In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of pre-existing immunity on messenger ribonucleic acid (mRNA) booster doses of BNT162b2 and mRNA-1273 vaccines ...

(RTTNews) - Biotechnology company Moderna, Inc. (MRNA) announced Wednesday new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. One month after administration in ...

Higher vaccine efficacy was observed with mRNA-1283 vs mRNA-1273.222 in individuals aged 65 years and older. A phase 3 trial evaluating Moderna’s next-generation COVID-19 vaccine, mRNA-1283, met its ...

Current data reveals no significant differences in the antibody responses to the XBB.1 variant of SARS-CoV-2 between the BA.4/BA.5 and BA.1 vaccines. While the precise formulation of future vaccine ...

In an observational study involving nearly 440,000 veterans, both the BNT162b2 vaccine and the mRNA-1273 vaccine were highly effective at preventing infection, hospitalization, and death from Covid-19 ...

CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new ...

OBJECTIVESTo evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. DESIGNTest negative ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the ...

In a randomized, placebo-controlled trial involving children 6 months to 5 years of age, the mRNA-1273 vaccine was shown to be safe, and the elicited antibody responses were similar to those in young ...